Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a pioneering clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a broad spectrum of cancers and immune diseases. The company's core innovation is the selective inhibition of interleukin-2-inducible T cell kinase (ITK), which plays a crucial role in T cell and natural killer (NK) cell immune functions. Corvus' lead investigational product, soquelitinib (formerly CPI-818), has shown promise in optimizing T cell differentiation and enhancing immune responses against tumors, as well as in the management of autoimmune diseases.
Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed peripheral T cell lymphoma (PTCL), an aggressive and typically treatment-resistant form of non-Hodgkin’s lymphoma. The company’s focus on ITK inhibition offers a new therapeutic approach, given the lack of FDA-approved treatments for relapsed PTCL. Soquelitinib has demonstrated the ability to prevent T cell exhaustion and promote the generation of cytotoxic killer T cells, critical in cancer therapy.
In addition, Corvus is investigating soquelitinib for other immune-mediated conditions, including atopic dermatitis. The company recently initiated a randomized, double-blind Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis, aiming to provide an oral treatment alternative to current injectable biologics.
Other promising candidates in Corvus' pipeline include ciforadenant, an adenosine A2A receptor inhibitor that disables tumors' immune evasion mechanisms, and mupadolimab, a monoclonal antibody targeting CD73. These candidates are being studied for their efficacy in combination therapies for various cancers, including head and neck cancers and non-small cell lung cancer.
Financially, Corvus maintains a strong position, having raised significant capital through direct offerings to support its clinical trials and operational needs. With cash reserves projected to fund operations into late 2025, Corvus is well-positioned to achieve substantial milestones in its clinical programs. The company continues to foster critical partnerships, including collaborations with Angel Pharmaceuticals for the Chinese market.
Latest news highlights Corvus' progress in clinical trials and strategic financing moves, underscoring its commitment to bringing innovative immunotherapies to patients in need. For more information, visit the Corvus Pharmaceuticals website.
Corvus Pharmaceuticals (CRVS) reported its Q1 2022 financial results, revealing cash reserves of $62.9 million, down from $69.5 million at the end of 2021. The net loss narrowed to $8.3 million compared to $11.6 million in Q1 2021. The company is advancing three clinical candidates, including mupadolimab for non-small cell lung cancer and ciforadenant for renal cell cancer, with trials set to start later in the year. Corvus will host an R&D Symposium on May 10, 2022, to discuss these clinical efforts.
Corvus Pharmaceuticals will host an R&D Symposium on May 10, 2022, in New York City, from 9:00 AM to 11:30 AM ET. The event aims to update on three clinical programs: anti-CD73 (mupadolimab), adenosine 2A receptor antagonist (ciforadenant), and ITK inhibitor (CPI-818) in T cell lymphomas. The symposium will feature insights from Corvus President Richard A. Miller, M.D., along with expert speakers from Stanford University and Angel Pharmaceuticals. The event will be webcast live and available for replay for 90 days.
Corvus Pharmaceuticals (Nasdaq: CRVS) provided a business update and 2021 financial results, highlighting progress in clinical programs targeting cancer. The firm plans a Phase 2 trial for mupadolimab in advanced non-small cell lung cancer and has expanded CPI-818 trials in China for T cell lymphomas. Cash reserves increased to $69.5 million from $44.3 million year-over-year, with a projected net cash usage of $34-$36 million in 2022. However, the net loss for 2021 was $43.2 million, a decline from a prior gain in 2020, primarily due to the absence of significant one-time gains.
Corvus Pharmaceuticals (Nasdaq: CRVS) will hold a conference call on March 10, 2022, at 4:30 pm ET to discuss business updates and report its Q4 and full year 2021 financial results. Investors can join the call by dialing 1-877-407-0784 for domestic or 1-201-689-8560 for international access. Registration requires the conference ID 13727689. The call will also be available via webcast, with a replay accessible on the company’s website for 90 days.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced that Angel Pharmaceuticals has commenced a Phase 1/1b clinical trial for CPI-818, a small molecule ITK inhibitor, targeting relapsed/refractory T-cell lymphomas in China. This marks the first clinical application of CPI-818 in the region, addressing a significant unmet clinical need, as T-cell lymphomas are more prevalent in China. The trial will assess various dosing regimens and evaluate safety, tolerability, and preliminary efficacy amongst patients who have failed standard therapies.
Corvus Pharmaceuticals announced promising preclinical data for CPI-818, an ITK inhibitor aimed at preventing acute graft versus host disease (aGVHD) during allogeneic bone marrow transplantation. Presented at the ASH Annual Meeting, the study showed that CPI-818 significantly improved GVHD scores and survival rates in mouse models, leading to increased anti-inflammatory cytokines and T suppressor cells. The company is advancing CPI-818 through a Phase 1/1b clinical trial, with potential for future trials targeting refractory T-cell lymphomas and autoimmune diseases.
Corvus Pharmaceuticals (CRVS) reported promising results from its Phase 1b clinical trial of mupadolimab, a monoclonal antibody targeting CD73, in patients with relapsed refractory non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). The study demonstrated tumor regression in patients resistant to prior anti-PD-1 therapy. Corvus is expanding patient enrollment in the trial and expects to release additional data in early 2022. Mupadolimab's unique mechanism may enhance immune responses and potentially overcome resistance to existing therapies.
BURLINGAME, Calif., Nov. 10, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) announced its participation at the Jefferies London Healthcare Conference from November 16-19, 2021. The company will engage in one-on-one meetings with investors. Additionally, a pre-recorded corporate overview presentation by CEO Richard A. Miller will be available on-demand starting at 3:00 am ET on November 18. Attendees can register for the webcast here, and the presentation will be accessible for 30 days post-event.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present data from its Phase 1/1b trial of mupadolimab at the 2021 SITC Annual Meeting, scheduled for November 10-14, 2021. The data presentation will focus on activating CD73 on B cells as a potential immunotherapy for HPV-positive head and neck cancers. A poster session will take place on November 12, 2021, and a conference call/webcast to discuss the findings is set for 9:00 am ET. Mupadolimab is a humanized monoclonal antibody designed to enhance immune response against cancers.
Corvus Pharmaceuticals (CRVS) provided a business update and reported third-quarter financial results for 2021. The company's cash and marketable securities increased to $76.3 million from $44.3 million at year-end 2020, largely due to stock offerings. Their lead drug, mupadolimab, is being tested in several trials for non-small cell lung cancer (NSCLC) and HPV+ head and neck cancers, with results expected in 2022. The company incurred a net loss of $10.7 million in Q3 2021, higher than the previous year’s $9.8 million loss, driven by increased clinical trial costs.
FAQ
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
What is the market cap of Corvus Pharmaceuticals (CRVS)?
What is Corvus Pharmaceuticals' lead product candidate?
What conditions is Corvus Pharmaceuticals targeting with soquelitinib?
What is the significance of ITK inhibition in Corvus Pharmaceuticals' research?
What other products are in Corvus Pharmaceuticals' pipeline?
What recent financial developments have supported Corvus Pharmaceuticals' research?
What is the background of Corvus Pharmaceuticals?
What partnerships does Corvus Pharmaceuticals have?
How is Corvus Pharmaceuticals addressing the unmet needs in relapsed PTCL?
How is soquelitinib being evaluated for atopic dermatitis?
What makes mupadolimab unique in Corvus Pharmaceuticals' research?
